1. The "AI-victim" mispricing screen — buy what the narrative orphaned
The repeatable method
- Build a list of stocks down hard and stuck in a downtrend with no breakout — the names the market reflexively dumps under a popular fear ("an AI victim," here).
- Separate price action from operating results. Pull the last 4–8 quarters of revenue, EBITDA, and free cash flow; flag any name whose fundamentals are improving while the stock falls.
- Ask whether the feared disruption is real or just a narrative — and what it would actually take for it to happen (a competitor building the moat from scratch).
- Demand a thrifty valuation floor (here ~0.6–0.8× sales) so you're paid to wait while the story is "unproven."
Here: QNST in a downtrend "perceived to be an AI victim," yet FY2025 revenue +78% and EBITDA +299% — the gap between the tape and the financials is the opportunity.
Watch for
- Stocks selling off on a thematic fear while reporting accelerating revenue/EBITDA; valuations that "price in failure."
2. Source-credentialing — weight an idea by the picker's track record
The repeatable method
- When an idea is sourced externally, evaluate the source's documented hit-rate before the thesis itself.
- Look for one undeniable, dated, public win (entry price, date, current price) as the credential — not a vague reputation.
- Treat a draft review by the source as added conviction, but still stress-test the bear case yourself.
Here: the idea comes from Sy Jacobs, whose prior Haymaker pick SII (Sprott) went from ~$34 (Dec 2023) to ~$120 — "350% gains in a bit over two years."
Watch for
- A specialist's concentrated, verifiable wins; ideas they've personally vetted vs second-hand tips.
3. The single-quarter shock as a moat-discovery signal
The repeatable method
- Hunt for a violent, single-quarter revenue spike in an out-of-favor vendor (here auto-insurance revenue +615% YoY) — it usually means a customer base suddenly needed what the vendor sells.
- Trace the macro cause (Covid scrambled auto-insurance economics → carriers desperate for leads) to confirm the demand is structural, not a one-off.
- Check whether the spike broadened (more carriers spending $1M+/month than ever) rather than concentrating in one client.
Here: QNST went "from written-off middleman to a must-have vendor in 18 months" as the rate-hike cycle drove insurance shopping onto its platform.
Watch for
- A demand shock that converts a commodity vendor into critical infrastructure; broad-based vs single-customer growth.
4. Stress-test the disintermediation bear case before buying the cheap stock
The repeatable method
- For any "middleman" trading cheap, name the existential threat explicitly (Google/Meta building the tool in-house).
- Apply the "they've had years and haven't" test — has the obvious disruptor already had time and incentive, and not done it? Ask why not (regulation, integration complexity, conflicting ad revenue).
- Identify the part of the moat that isn't replicable cheaply (here QRP's 100+ carrier integrations + issuance — "the juice might not be worth the squeeze").
Here: Google has had 15+ years to build a comparative rater at scale and hasn't — it earns more selling ads to everyone, and insurance is regulated state-by-state.
Watch for
- A feared disruptor with the means but not the motive; switching costs once a platform is embedded in workflows.
5. The margin-milestone re-rating math — value the inflection, not the trailing print
The repeatable method
- Take management's explicit margin target (here 10% EBITDA, from ~7.3%) and apply it to guided revenue to get forward EBITDA.
- Apply a defensible multiple range (10–12× for a high-growth digital platform) to get an implied market cap and per-share value.
- Sanity-check that gross cash flow ≈ free cash flow (no interest, modest depreciation, non-cash amortization) so the EBITDA is "real."
Here: 10% margins on $1.3B revenue = $130M EBITDA; at 10–12× that's $1.3–1.6B cap ≈ $23–28/share vs ~$11 today.
Watch for
- A credible margin-expansion path applied to guided revenue; whether EBITDA converts to actual cash.
6. The accretive bolt-on as a "purely additive" call option
The repeatable method
- When a turnaround buys a business, check whether it's funded conservatively (here $45M cash + a credit line, leaving ~zero net debt) and immediately cash-flow positive.
- Treat year-one accretion as the floor, with un-modeled synergies as upside — but don't pay for synergies until they show.
- Prefer deals that add a new capability (HomeBuddy's social/native reach + auction-exclusive leads), not just more of the same.
Here: HomeBuddy ($115M, closed Jan 2026) expected to add $30M+ year-one EBITDA — guidance treats it as "purely additive and accretive."
Watch for
- Self-funding, immediately-accretive bolt-ons that diversify the revenue engine rather than concentrate it.
7. Size to the conviction — small for a "demonstrated but unproven moat"
The repeatable method
- Match position size to where the thesis sits on the proven/unproven spectrum — a moat that's "demonstrated but unproven" warrants a smaller stake.
- Average into the position rather than buying all at once, especially on a name with no broken downtrend.
- Define the confirmation that would let you add: "if the next few quarters confirm the turnaround is real, the stock likely re-rates."
Here: risk-averse investors take "a relatively small position," bolder ones a bigger one — "as always, we prefer to average into new opportunities."
Watch for
- The next 1–2 quarterly confirmations as the trigger to scale up; sideways-to-down if the story resets.